Floatz logo

Lanreotide

Prostate Cancer

Ipsenprotein_peptidePhase 3Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
59/ 100

Competitive context

514 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

Lanreotide is also rated in:

lymphoceleDormant
BB
Indicative ·
64 / 100
View asset →
malignant endocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
non-functional pancreatic neuroendocrine tumorDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →